A Phase 3, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety of Tramadol Infusion (AVE-901) in the Management of Post-Operative Pain Following Surgery
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Tramadol (Primary)
- Indications Postoperative pain
- Focus Adverse reactions; Registrational
- Sponsors Avenue Therapeutics
- 04 Nov 2019 According to an Avenue Therapeutics media release, the company is on track to submit a New Drug Application for IV tramadol to the U.S. Food and Drug Administration by year-end 2019.
- 07 May 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Jan 2018 According to an Avenue Therapeutics media release, the first patients have been dosed in this trial. The results of this trial will support a new drug application (NDA), which the company expects to submit to the US FDA in late 2019.